ScottHKaufmannMDPhD

Hematology • Rochester, MN

Hematologic Oncology

Consultant in Hematology Mayo Clinic Rochester, MN

Join to view full profile

Dr. Kaufmann is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kaufmann's full profile

Already have an account?

Office
200 1st St Sw
Rochester, MN 55905
Phone+1 507-284-2511

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1985 - 1987
Johns Hopkins UniversityResidency, Internal Medicine, 1982 - 1985
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1981 - 1982
Johns Hopkins University School of MedicineClass of 1981

Certifications & Licensure

MN State Medical License 1995 - 2025
MD State Medical License 1985 - 1994
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Recurrent Acute Leukemia Start of enrollment: 1995 Oct 01
Completed
Phase 1
Carboplatin Plus Topotecan in Treating Patients With Relapsed Acute Myelogenous Leukemia Start of enrollment: 1999 Nov 01
Completed
Phase 2
Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes Start of enrollment: 2004 Nov 01
Completed
Phase 1
CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 2005 May 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

986 citations
PARP inhibition: PARP1 and beyond
Michèle Rouleau, Anand G. Patel, Michael J. Hendzel, Scott H. Kaufmann, Guy G. Poirier
Nature Reviews. Cancer. 2010-03-04
271 citations
Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
Clare L. Scott, Elizabeth M. Swisher, Scott H. Kaufmann
Journal of Clinical Oncology. 2015-04-20
508 citations
The Current Status of Camptothecin Analogues as Antitumor Agents
William Slichenmyer, Eric K. Rowinsky, Ross C. Donehower, Scott H. Kaufmann
Journal of the National Cancer Institute. 1993-02-17

Journal Articles

Methylation of All BRCA1 Copies Predicts Response to the PARP Inhibitor Rucaparib in Ovarian Carcinoma
Scott H Kaufmann, Elizabeth M Swisher, Nature

Abstracts/Posters

A Multisite Phase Ib Study of Pevonedistat, Azacitidine and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML)
Scott H. Kaufmann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic S...
Scott H. Kaufmann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Press Mentions

The Deubiquitinase USP36 Regulates DNA Replication Stress and Confers Therapeutic Resistance Through PrimPol StabilizationNovember 25th, 2020

Grant Support

Anticancer Drug-Induced Bh3-Only Protein.Bak InteractionsNational Cancer Institute2012
Poisoning Of PARP And Topoisomerase I To Treat Ovarian CancerNational Cancer Institute2009–2011
Developmental Research ProgramNational Cancer Institute2009–2011
Role Of Proteases In Therapy-Induced ApoptosisNational Cancer Institute2006–2010
Topoisomerase I Inhibitors In Leukemia And Solid TumorsNational Cancer Institute2004–2010
Preclinical Evaluation Of Bcr/Abl-Directed TyrphostinsNational Cancer Institute2004–2007
Multidisciplinary Training In Experimental HematologyNational Heart, Lung, And Blood Institute2004–2005
Role Of Proteases In Chemotherapy Induced ApoptosisNational Cancer Institute2004–2005
Role Of Proteases In Chemotherapy Induced ApoptosisNational Cancer Institute2002–2003
Multidisciplinary Training In Experimental HematologyNational Heart, Lung, And Blood Institute2001–2003
Topoisomerase I Inhibitors In Leukemia And Solid TumorsNational Cancer Institute1997–2003
Preclinical Evaluation Of BCR/ABL Directed TyrphostinsNational Cancer Institute2000–2002
Proteases And Chemotherapy Induced ApoptosisNational Cancer Institute1995–2001
Novel Mechanism Of Multiple Drug ResistanceNational Cancer Institute1995–1998
Gordon Conference On ChemotherapyNational Cancer Institute1997
Mechanism Of Cytotoxicity Of Topoisomerase II PoisonsNational Cancer Institute1994
Mechanism Of Cytotoxicity Of Topoisomerase II PoisonsNational Cancer Institute1992–1994
Topoisomerase II And Drug Resistance In Acute LeukemiaNational Cancer Institute1989–1991
Analysis Of Nonlamin Nuclear Envelope PolypeptidesNational Institute Of General Medical Sciences1985